Investigational drug · Phase 3
KRT-232
Also called: Navtemadlin
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
19
Any phase or sponsor naming "KRT-232"
First trial start
2019
Jan 15, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KRT-232", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Large B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma
- Endometrial Cancer
- Polycythemia Vera
- Myelofibrosis
- Post-PV MF
- Post-ET Myelofibrosis
- Primary Myelofibrosis
- MF
Approved drugs for the same conditions: Endometrial cancer · Chronic lymphocytic leukemia · Hodgkin lymphoma · Myelofibrosis · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "KRT-232" as an intervention, largest first.
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibPivotal-lookingRecruiting
Kartos Therapeutics, Inc.Industry
NCT06479135 · 600 participants (planned) · Start Jun 3, 2024 · Primary completion Dec 31, 2026
Drug: Navtemadlin; Navtemadlin placebo and 1 more · For: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis and 2 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 215 sites in all
- KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentPivotal-lookingStatus unknown
Kartos Therapeutics, Inc.Industry
NCT03662126 · 385 participants (planned) · Start Jan 15, 2019 · Primary completion Dec 31, 2023
Drug: KRT-232; Best Available Therapy (BAT) · For: Primary Myelofibrosis (PMF); Post-Polycythemia Vera MF (Post-PV-MF); Post-Essential Thrombocythemia MF (Post-ET-MF)
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 191 sites in all
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerPivotal-lookingRecruiting
Kartos Therapeutics, Inc.Industry
NCT05797831 · 268 participants (planned) · Start Jul 17, 2023 · Primary completion Aug 2025
Drug: Navtemadlin; Navtemadlin Placebo · For: Endometrial Cancer
Sites: Vallejo, California; Atlanta, Georgia; Savannah, Georgia · 83 sites in all
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFPivotal-lookingStatus unknown
Kartos Therapeutics, Inc.Industry
NCT04640532 · 116 participants (planned) · Start Nov 17, 2020 · Primary completion May 11, 2022
Drug: KRT-232; TL-895 · For: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis and 1 more
Sites: Birmingham, Alabama; Whittier, California; Lake City, Florida · 37 sites in all
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaPivotal-lookingStatus unknown
Kartos Therapeutics, Inc.Industry
NCT03787602 · 115 participants (planned) · Start Mar 19, 2019 · Primary completion Nov 2024
Drug: KRT-232; Avelumab · For: Merkel Cell Carcinoma
Sites: Aurora, Colorado; Miami, Florida; Tampa, Florida · 51 sites in all
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaStatus unknown
Kartos Therapeutics, Inc.Industry
NCT04835584 · 109 participants (planned) · Start May 7, 2021 · Primary completion Dec 31, 2024
Drug: KRT-232; Dasatinib and 1 more · For: Chronic Myeloid Leukemia
Sites: Birmingham, Alabama; Augusta, Georgia; Pittsburgh, Pennsylvania · 26 sites in all
Kartos Therapeutics, Inc.Industry
NCT04502394 · 84 participants (planned) · Start Feb 23, 2021 · Primary completion Oct 2022
Drug: KRT-232; acalabrutinib · For: Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma
Sites: Goshen, Indiana; Cincinnati, Ohio; Columbus, Ohio · 45 sites in all
Kartos Therapeutics, Inc.Industry
NCT04113616 · 70 participants · Start Sep 25, 2019 · Primary completion Sep 27, 2023
Drug: KRT-232; Cytarabine and 1 more · For: Relapsed or Refractory Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Sites: Chicago, Illinois; Baltimore, Maryland; New York, New York · 59 sites in all
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid LeukemiaActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03041688 · 58 participants (planned) · Start Feb 8, 2018 · Primary completion Jun 30, 2027
Drug: Decitabine; Navtemadlin and 1 more · For: Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia and 1 more
Sites: Duarte, California; Los Angeles, California; Pasadena, California · 13 sites in all
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisStatus unknown
Kartos Therapeutics, Inc.Industry
NCT04878003 · 52 participants (planned) · Start Apr 13, 2021 · Primary completion May 2024
Drug: KRT-232; TL-895 · For: Primary Myelofibrosis (PMF); Post-Polycythemia Vera Myelofibrosis (Post-PV-MF); Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Sites: Glendale, California; Whittier, California; Canton, Ohio · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells.
Boix de Jesus A, Dao HB, Imani A, et al. · Front Immunol 2026
- The Path Forward in MF: Small Molecules in the Limelight.
Abruzzese E, Trawinska MM, Bernardi S, et al. · Cancers (Basel) 2026
- Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
Aluri A, Kishtagari A · Semin Hematol 2026
- POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
Vachhani P, Yacoub A, Rampal R, et al. · Future Oncol 2026
- Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups.
Mikhaylenko N, Braun T, Timonen S, et al. · Biol Direct 2025
- Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma.
Vaubel RA, Zhang W, Oh JH, et al. · Clin Cancer Res 2025
Also in development for Diffuse Large B Cell Lymphoma
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- TQB2825Phase 33 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Diffuse Large Cell B-lymphoma
- CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials
Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
- TulmimetostatDZR123, Tulmimetostat DL1Phase 23 trials
Novartis · Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advanced Solid Tumor
- and prednisonePhase 22 trials
Genmab · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- IMT-009Phase 21 trial
Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.